Álvaro Taus

1.8k total citations
63 papers, 874 citations indexed

About

Álvaro Taus is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Álvaro Taus has authored 63 papers receiving a total of 874 indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 19 papers in Cancer Research. Recurrent topics in Álvaro Taus's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (16 papers) and Lung Cancer Research Studies (13 papers). Álvaro Taus is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (16 papers) and Lung Cancer Research Studies (13 papers). Álvaro Taus collaborates with scholars based in Spain, United Kingdom and United States. Álvaro Taus's co-authors include Edurne Arriola, Lara Pijuán, Joan Albanell, Marta Salido, Sílvia Menéndez, Pedro Rocha, Sergi Clavé, Ana Rovira, Oriol Arpí and David Casadevall and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Álvaro Taus

63 papers receiving 866 citations

Peers

Countries citing papers authored by Álvaro Taus

Since Specialization

Citations

This map shows the geographic impact of Álvaro Taus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Álvaro Taus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Álvaro Taus more than expected).

Fields of papers citing papers by Álvaro Taus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Álvaro Taus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Álvaro Taus. The network helps show where Álvaro Taus may publish in the future.

Co-authorship network of co-authors of Álvaro Taus

This figure shows the co-authorship network connecting the top 25 collaborators of Álvaro Taus. A scholar is included among the top collaborators of Álvaro Taus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Álvaro Taus. Álvaro Taus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Non-bacterial thrombotic endocarditis in ROS1-rearranged lung cancer: a report of two cases 2024 ·Translational Lung Cancer Research ·(unknown), (unknown), (unknown), Pedro Rocha, Álvaro Taus, Edurne Arriola	2
2	Safety and Efficacy of Crizotinib in Combination with Temozolomide and Radiotherapy in Patients with Newly Diagnosed Glioblastoma: Phase Ib GEINO 1402 Trial 2022 ·Cancers ·Maria Martinez‐García, Guillermo Velasco, Estela Pineda, Miguel Gil‐Gil, Francesc Alameda, Jaume Capellades, (unknown), Israel López-Valero, (unknown), P. Foro, Álvaro Taus, (unknown), Aurelio Hernández‐Laín, Juan Manuel Sepúlveda-Sánchez	16
3	Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study 2022 ·British Journal of Cancer ·Alejo Rodríguez‐Vida, Pablo Maroto, Albert Font, Cristina Martín, Begoña Mellado, (unknown), Mayra Orrillo, Òscar Reig, (unknown), Alejandro Ríos-Hoyo, (unknown), Judith Alonso, (unknown), (unknown), Álvaro Taus, Maria Martinez‐García, Núria Juanpere, Óscar Juan, Joaquim Bellmunt	9
4	Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma 2020 ·Archivos de Bronconeumología ·Álvaro Taus, (unknown), Pedro Rocha, Ainhoa Hernández, Raquel Longarón, Sergi Clavé, (unknown), Marta Salido, (unknown), Concepción Fernández‐Rodríguez, Joan Albanell, Beatríz Bellosillo, Edurne Arriola	2
5	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non–small-cell Lung Cancer: Implications of FISH-positive Patterns 2019 ·Clinical Lung Cancer ·Sergi Clavé, (unknown), Lara Pijuán, (unknown), Marta Lorenzo, Pedro Rocha, Álvaro Taus, Remei Blanco, Joaquim Bosch‐Barrera, Noemı́ Reguart, (unknown), Glòria Oliveras, Blanca Espinet, Beatríz Bellosillo, Xavier Puig, Edurne Arriola, Marta Salido	33
6	P2.09-34 Next-Generation Sequencing Implementation in Non-Small Cell Lung Cancer Molecular Diagnosis 2019 ·Journal of Thoracic Oncology ·Sergi Clavé, Beatríz Bellosillo, Marta Salido, (unknown), Álvaro Taus, Pedro Rocha, (unknown), (unknown), (unknown), Concepción Fernández‐Rodríguez, Edurne Arriola, Lara Pijuán	1
7	<p>Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date</p> 2019 ·Cancer Management and Research ·Jordi Remón, (unknown), Álvaro Taus	8
8	Dynamic Treatment Stratification Using ctDNA 2019 ·Recent results in cancer research ·Joana Vidal, Álvaro Taus, Clara Montagut	12
9	CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC 2018 ·Journal of Thoracic Oncology ·Pedro Rocha, (unknown), (unknown), Álvaro Taus, Maria Teresa Rodrigo‐Calvo, Flavio Zuccarino, (unknown), Oliver Wood, Christian H. Ottensmeier, Edurne Arriola	24
10	Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma 2018 ·Clinical Lung Cancer ·Álvaro Taus, (unknown), Pedro Rocha, (unknown), Lara Pijuán, (unknown), Eva López, Alba Dalmases, Raquel Longarón, Sergi Clavé, Marta Salido, Joan Albanell, Beatríz Bellosillo, Edurne Arriola	44
11	Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA) 2018 ·Annals of Oncology ·Niki Karachaliou, Martina I. Lefterova, (unknown), (unknown), Imane Chaib, Ramón Palmero, Álvaro Taus, Santiago Viteri, María González Cao, M. Majem Tarruella, Enric Carcereny, Teresa Morán, J. Garde, E. Felip Font, S. Olsen, Mary Jackson, (unknown), Iris Faull, Daniel Dix, Rafael Rosell	1
12	P1.02-048 MET Exon 14 Skipping Mutations and Gene Amplifications Are Not Simultaneous Events in NSCLC 2017 ·Journal of Thoracic Oncology ·Sergi Clavé, Alba Dalmases, Raquel Longarón, Lara Pijuán, David Casadevall, Álvaro Taus, Joan Albanell, Blanca Espinet, Edurne Arriola, Beatríz Bellosillo, Marta Salido	1
13	P1.15-001 Ipilimumab Increases Th1/Th2 and Inflammatory Cytokines Counteracting Chemotherapy Effects in Small Cell Lung Cancer 2017 ·Journal of Thoracic Oncology ·(unknown), Pedro Rocha, Oriol Arpí, Álvaro Taus, Deborah Joseph-Pietras, Ana Rovira, Joan Albanell, Christian H. Ottensmeier, Edurne Arriola	1
14	P1.02-039 Assessment of KRAS mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients 2017 ·Journal of Thoracic Oncology ·Álvaro Taus, (unknown), Ainhoa Hernández, (unknown), Eva López, Alba Dalmases, David Casadevall, Lara Pijuán, (unknown), Raquel Longarón, Pedro Rocha, (unknown), Joan Albanell, Beatríz Bellosillo, Edurne Arriola	1
15	4P Co-amplifications of PD-L1/PD-L2 genes (9p24.1) and PD-L1 protein expression in NSCLC patients 2016 ·Journal of Thoracic Oncology ·Sergi Clavé, David Casadevall, Lara Pijuán, (unknown), (unknown), Álvaro Taus, Joan Albanell, Blanca Espinet, Edurne Arriola, Marta Salido	2
16	A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer 2016 ·Annals of Oncology ·Juan Miguel Cejalvo, Tania Fleitas, Enriqueta Felip, Alejandro Navarro, Maria Martinez‐García, Álvaro Taus, Natasha B. Leighl, Ulrik Lassen, (unknown), Céline Adessi, Francesca Michielin, Wolfgang Jacob, Ian James, Maurizio Ceppi, Maja Weisser, Andrés Cervantes	3
17	Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? 2015 ·World Journal of Clinical Oncology ·Edurne Arriola, Álvaro Taus, David Casadevall	4
18	Methylation status ofIGFBP-3as a useful clinical tool for deciding on a concomitant radiotherapy 2014 ·Epigenetics ·Olga Pernía, Cristóbal Belda-Iniesta, Verónica Pulido, María Cortés-Sempere, Carlos Rodríguez‐Antolín, Olga Vera, Javier Soto, (unknown), Álvaro Taus, Federico Rojo, Edurne Arriola, Ana Rovira, Joan Albanell, (unknown), Javier de Castro, Rosario Perona, Inmaculada Ibañez de Cáceres	11
19	Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer 2013 ·Clinical Cancer Research ·Israel Cañadas, Federico Rojo, Álvaro Taus, Oriol Arpí, Montserrat Arumí-Uría, Lara Pijuán, Sílvia Menéndez, Sandra Zazo, Manuel Dómine, Marta Salido, Sergi Mojal, Antonio Garcı́a de Herreros, Ana Rovira, Joan Albanell, Edurne Arriola	107
20	Neumonía organizada asociada a tratamiento con trastuzumab 2009 ·Archivos de Bronconeumología ·Álvaro Taus, Albert Sánchez‐Font, (unknown), Lara Pijuán, (unknown), Víctor Curull	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact